Literature DB >> 17587094

The molecular basis of urokinase inhibition: from the nonempirical analysis of intermolecular interactions to the prediction of binding affinity.

Renata Grzywa1, Edyta Dyguda-Kazimierowicz, Marcin Sieńczyk, Mikołaj Feliks, W Andrzej Sokalski, Józef Oleksyszyn.   

Abstract

Urokinase-type plasminogen activator (uPA) is a trypsin-like serine protease that plays a crucial role in angiogenesis process. In addition to its physiological role in healthy organisms, angiogenesis is extremely important in cancer growth and metastasis, resulting in numerous attempts to understand its control and to develop new approaches to anticancer therapy. The alpha-aminoalkylphosphonate diphenyl esters are well known as highly efficient serine protease inhibitors. However, their mode of binding has not been verified experimentally in details. For a group of average and potent phosphonic inhibitors of urokinase, flexible docking calculations were performed to gain an insight into the active site interactions responsible for observed enzyme inhibition. The docking results are consistent with the previously suggested mode of inhibitors binding. Subsequently, rigorous ab initio study of binding energy was carried out, followed by its decomposition according to the variation-perturbation procedure to reveal stabilization energy constituents with clear physical meaning. Availability of the experimental inhibitory activities and comparison with theoretical binding energy allows for the validation of theoretical models of inhibition, as well as estimation of the possible potential for binding affinity prediction. Since the docking results accompanied by molecular mechanics optimization suggested that several crucial active site contacts were too short, the optimal distances corresponding to the minimum ab initio interaction energy were also evaluated. Despite the deficiencies of force field-optimized enzyme-inhibitor structures, satisfactory agreement with experimental inhibitory activity was obtained for the electrostatic interaction energy, suggesting its possible application in the binding affinity prediction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587094     DOI: 10.1007/s00894-007-0193-8

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  21 in total

Review 1.  The microenvironment of the tumour-host interface.

Authors:  L A Liotta; E C Kohn
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate.

Authors:  Ewa Zesławska; Uwe Jacob; Jörg Stürzebecher; Barbara J Oleksyn
Journal:  Bioorg Med Chem Lett       Date:  2005-10-03       Impact factor: 2.823

Review 3.  Cell migration: regulation of force on extracellular-matrix-integrin complexes.

Authors:  M P Sheetz; D P Felsenfeld; C G Galbraith
Journal:  Trends Cell Biol       Date:  1998-02       Impact factor: 20.808

Review 4.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

5.  Amino acid and peptide phosphonate derivatives as specific inhibitors of serine peptidases.

Authors:  J Oleksyszyn; J C Powers
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

6.  Irreversible inhibition of serine proteases by peptidyl derivatives of alpha-aminoalkylphosphonate diphenyl esters.

Authors:  J Oleksyszyn; J C Powers
Journal:  Biochem Biophys Res Commun       Date:  1989-05-30       Impact factor: 3.575

7.  Origins of the activity of PAL and LAP enzyme inhibitors: toward ab initio binding affinity prediction.

Authors:  Edyta Dyguda; Jolanta Grembecka; W Andrzej Sokalski; Jerzy Leszczyński
Journal:  J Am Chem Soc       Date:  2005-02-16       Impact factor: 15.419

8.  Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.

Authors:  J Joossens; P Van der Veken; A-M Lambeir; K Augustyns; A Haemers
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

Review 9.  Inhibitors of the proteolytic activity of urokinase type plasminogen activator.

Authors:  Todd W Rockway; Vincent L Giranda
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

Review 10.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

View more
  5 in total

1.  Universal short-range ab initio atom-atom potentials for interaction energy contributions with an optimal repulsion functional form.

Authors:  Jan K Konieczny; W Andrzej Sokalski
Journal:  J Mol Model       Date:  2015-07-14       Impact factor: 1.810

2.  Application of a simple quantum chemical approach to ligand fragment scoring for Trypanosoma brucei pteridine reductase 1 inhibition.

Authors:  Wiktoria Jedwabny; Joanna Panecka-Hofman; Edyta Dyguda-Kazimierowicz; Rebecca C Wade; W Andrzej Sokalski
Journal:  J Comput Aided Mol Des       Date:  2017-07-07       Impact factor: 3.686

3.  Theoretical models of inhibitory activity for inhibitors of protein-protein interactions: targeting menin-mixed lineage leukemia with small molecules.

Authors:  Wiktoria Jedwabny; Szymon Kłossowski; Trupta Purohit; Tomasz Cierpicki; Jolanta Grembecka; Edyta Dyguda-Kazimierowicz
Journal:  Medchemcomm       Date:  2017-09-12       Impact factor: 3.597

4.  Theoretical Model of EphA2-Ephrin A1 Inhibition.

Authors:  Wiktoria Jedwabny; Alessio Lodola; Edyta Dyguda-Kazimierowicz
Journal:  Molecules       Date:  2018-07-11       Impact factor: 4.411

5.  Extension of an Atom-Atom Dispersion Function to Halogen Bonds and Its Use for Rational Design of Drugs and Biocatalysts.

Authors:  Wiktoria Jedwabny; Edyta Dyguda-Kazimierowicz; Katarzyna Pernal; Krzysztof Szalewicz; Konrad Patkowski
Journal:  J Phys Chem A       Date:  2021-02-23       Impact factor: 2.781

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.